Enanta Pharmaceuticals In... (ENTA)
NASDAQ: ENTA
· Real-Time Price · USD
7.20
0.91 (14.47%)
At close: Jun 03, 2025, 3:59 PM
7.54
4.79%
After-hours: Jun 03, 2025, 07:15 PM EDT
Enanta Pharmaceuticals Revenue Breakdown
| Period Ending | Sep 30, 2024 | Sep 30, 2023 | Sep 30, 2021 | Sep 30, 2020 | Sep 30, 2019 | Sep 30, 2018 |
|---|---|---|---|---|---|---|
| Royalty Revenue | 67.64M | 78.2M | 97.07M | 122.47M | 205.2M | 191.63M |
| Royalty Revenue Growth | -13.51% | -19.44% | -20.74% | -40.31% | +7.08% | n/a |
Operating Expense Breakdown
| Period Ending | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General, and Administrative Revenue | 11.39M | 12.85M | 13.68M | 13.41M | 14.23M | 16.52M | 13.79M | 12.62M | 13.78M | 12.7M | 12.57M | 12.93M | 10.48M | 9.51M | 8.36M | 8.48M | 8.33M | 7.38M | 6.73M | 6.82M | 6.88M | 6.92M | 6.16M | 6.15M | 6.78M | 7.15M | 5.83M | 6.13M | 5.71M | 5.77M | 5.12M | 5.23M | 5.46M | 4.94M | 4.44M | 4.28M | 4.43M | 3.82M | 3.69M | 3.64M | 3.44M |
| Selling, General, and Administrative Revenue Growth | -11.35% | -6.12% | +2.01% | -5.77% | -13.82% | +19.74% | +9.33% | -8.42% | +8.52% | +1.01% | -2.78% | +23.42% | +10.18% | +13.79% | -1.43% | +1.81% | +12.86% | +9.65% | -1.39% | -0.89% | -0.53% | +12.30% | +0.20% | -9.28% | -5.20% | +22.68% | -4.97% | +7.52% | -1.11% | +12.74% | -2.20% | -4.18% | +10.61% | +11.19% | +3.69% | -3.25% | +15.92% | +3.38% | +1.37% | +5.96% | n/a |
| Research and Development Revenue | 28.07M | 27.66M | 30.78M | 28.74M | 35.59M | 36.37M | 36.17M | 42.99M | 43.47M | 40.9M | 34.8M | 39.09M | 42.09M | 48.55M | 48.95M | 46.99M | 41.51M | 36.66M | 36.69M | 34.68M | 32.61M | 32.78M | 38.72M | 34.46M | 34.16M | 34.88M | 26.92M | 28.49M | 21.48M | 17.96M | 16.51M | 15.41M | 13M | 12.53M | 11.5M | 10.79M | 9.14M | 9.03M | 7.05M | 6.25M | 5.37M |
| Research and Development Revenue Growth | +1.48% | -10.14% | +7.08% | -19.23% | -2.16% | +0.56% | -15.87% | -1.11% | +6.27% | +17.55% | -10.98% | -7.12% | -13.31% | -0.81% | +4.15% | +13.22% | +13.20% | -0.06% | +5.78% | +6.35% | -0.51% | -15.34% | +12.36% | +0.90% | -2.07% | +29.55% | -5.49% | +32.60% | +19.61% | +8.77% | +7.19% | +18.48% | +3.82% | +8.92% | +6.63% | +17.96% | +1.22% | +28.15% | +12.73% | +16.49% | n/a |